Haratake N, Hayashi H, Shimokawa M, Nakano Y, et al. Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). Clin Lung Cancer 2021 Oct 24. pii: S1525-7304(21)00270.
PMID: 34887192